作为深耕生物科技领域的国际投行,今年以来,摩根士丹利保荐了恒瑞医药、映恩生物、维立志博等标志性港股IPO项目,并完成了药明康德9.8亿美元、信达生物5.5亿美元、翰森制药约5亿美元等多个再融资项目。 近日,券商中国记者专访了摩根士丹利亚太股权资本市场主管张晓羽、亚太医疗投资银行主管孙锶铭,从投行角度洞察中国创新药行业正在发生的巨变。 张晓羽认为,今年以来,国际投资者对中国生物科技企业的关注度持续...
Source Link作为深耕生物科技领域的国际投行,今年以来,摩根士丹利保荐了恒瑞医药、映恩生物、维立志博等标志性港股IPO项目,并完成了药明康德9.8亿美元、信达生物5.5亿美元、翰森制药约5亿美元等多个再融资项目。 近日,券商中国记者专访了摩根士丹利亚太股权资本市场主管张晓羽、亚太医疗投资银行主管孙锶铭,从投行角度洞察中国创新药行业正在发生的巨变。 张晓羽认为,今年以来,国际投资者对中国生物科技企业的关注度持续...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.